Metzler Research

Takkt No reasons to become more optimistic after Q2/19

Zooplus We still see no turnaround

Takkt Current share price level well reflects weakening topline momentum

Shop Apotheke Europe Slightly weaker growth in Q2 - but no cause for concern

Zooplus Recent share price hike offers good selling opportunity

capm daily: Focus markets: The cheap money drug + E-prescription in the starting blocks

capm daily: Focus UK: "Drowning" Street No. 10 + Chewy vs. Zooplus

Home24 Worth a gamble at current share price level

capm daily: Focus USA: Trade war and economic weakness + Aggravation instead of all-clear